September 2022 in “Journal of pharmaceutical sciences” Thicker minoxidil solutions work better and need less frequent application.
53 citations,
April 2018 in “Journal of The American Academy of Dermatology” Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.
October 2024 in “International Journal of Pharmaceutical Sciences Review and Research” This study explores a film-forming spray with 5% minoxidil for treating androgenetic alopecia, aiming to reduce side effects like dry scalp and irritation associated with traditional formulations. The spray forms a thin, non-sticky film that enhances drug contact time and permeability, leading to continuous release and improved patient comfort. The formulation was evaluated for pH, viscosity, spray angle, and drug content, with formulation F2 (1.8% hydroxypropyl methylcellulose E15) showing promising results. The study concludes that this novel delivery system could effectively treat patchy hair loss or baldness in men with androgenetic alopecia, improving therapeutic outcomes and patient compliance.
January 2010 in “Elsevier eBooks” The document concludes that different types of hair loss have specific treatments, and early diagnosis is crucial for preventing permanent hair loss.
131 citations,
October 2004 in “Clinical Cancer Research” Tempol is safe and may prevent hair loss from brain radiotherapy.